Skip to main content
HairCited

Current Treatment of Alopecia Areata.

Maria K Hordinsky
Other The journal of investigative dermatology. Symposium proceedings 2020 3 citations
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D33099380'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Type d'étude
Other
Population
None
Intervention
Current Treatment of Alopecia Areata. None
Comparateur
None
Critère de jugement principal
None
Direction de l'effet
Mixed
Risque de biais
Unclear

Abstract

The number of alopecia areata (AA) clinical trials with Jak inhibitors of cytoplasmic tyrosine kinases, including Jak1, Jak2, Jak3, and tyrosine-protein kinase has increased significantly since the last Research Summit. This fact means that the conversation about current treatments for AA now also needs to include a discussion of traditionally used off-label therapies as well as evolving therapies as with Jak inhibitors.

En bref

The number of alopecia areata clinical trials with Jak inhibitors of cytoplasmic tyrosine kinases has increased significantly since the last Research Summit, which means that the conversation about current treatments for AA now also needs to include a discussion of traditionally used off-label therapies.

Used In Evidence Reviews

Similar Papers